A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular...

Full description

Bibliographic Details
Main Authors: Tomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, Laia Paré, Emilio Alba, Álvaro Rodríguez-Lescure, Giuseppe Perrone, Javier Cortés, Serafín Morales, Ana Lluch, Ander Urruticoechea, Blanca González-Farré, Patricia Galván, Pedro Jares, Adela Rodriguez, Nuria Chic, Daniela Righi, Juan Miguel Cejalvo, Giuseppe Tonini, Barbara Adamo, Maria Vidal, Patricia Villagrasa, Montserrat Muñoz, Aleix Prat
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Oncology
Subjects:
intrinsic subtype
non-luminal
PAM50
breast cancer
gene expression
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00303/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00303/full

Similar Items